Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer

被引:1
作者
Marinova, Dora Marinova [1 ,2 ]
Mekov, Evgeni Vitkov [1 ,2 ]
Dimitrova, Denitsa Gosheva [1 ,2 ]
Titorenkov, Plamen Todorov [3 ]
Mihailov, Miroslav Martinov [1 ,2 ]
Nachev, Sevdalin Slavov [4 ]
Youroukova, Vania Milosheva [1 ,2 ]
Kostadinov, Dimitar Temelkov [1 ,5 ]
Slavova, Yanina Georgieva [1 ,6 ]
机构
[1] Med Univ, Clin Ctr Lung Dis, Sofia, Bulgaria
[2] Univ Hosp Pulm Dis St Sofia, Dept Pneumonol, Sofia, Bulgaria
[3] Sofia Univ, Mil Med Acad, Fac Med, Sofia, Bulgaria
[4] Univ Hosp St Ivan Rilski, Dept Pathol, Sofia, Bulgaria
[5] Univ Hosp Pulm Dis St Sofia, Dept Bronchol, Sofia, Bulgaria
[6] Univ Hosp Pulm Dis St Sofia, Dept Pathol, Sofia, Bulgaria
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
brain metastases; immunohistochemistry; lung cancer; CELL CARCINOMA; SURVIVAL; PATTERN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study brain metastases (BM) and their corresponding primary lung cancers (LCs). Methods: Surgically resected BMs and their corresponding primary LCs from 30 patients (25 men, 83%, age 55 +/- 9 years) were studied: 21 adenocarcinomas (ACs), 5 squamous cell carcinomas (SCCs), 4 small cell lung carcinomas (SCLCs). The histological subtype, immunohistochemical expression of TTF1, p63, Ki67 (proliferative activity), CD31, number of intratumoral microvessels, (NIM) and survival were evaluated. Results: There was a different histological structure in 47% of the cases of ACs of the lung in comparison with the corresponding metastasis, but none in SCC and SCLC. TTF-1 was expressed in a greater number of ACs (n=20; 95%), with lower mean expression levels, while the corresponding BM expressed the marker less frequently (n=16; 76%) with higher mean expression values (p=0.011). P63 was expressed in all SCCs (p=0.68). Cytokeratin 7 was expressed equally in all ACs. Ki-67 proliferative index (PI) was higher in SCLC than in AC (p=0.008), in SCLC BM than in AC BM (p<0.001), and in SCLC BM than in SCC BM (p=0.008). The Ki-67 PI in BM was higher than in AC (p=0.003), SCC (p=0.048), but without difference in SCLC (p=0.141). CD31 NIM was higher in AC than in SCLC (p=0.003), in SCC than in SCLC (p=0.009), while no difference between AC and SCC was found (p=0.467). There were no differences between LC/BM in the NIM. Survival after surgery for LC was significantly longer in AC than in SCLC (p=0.017). SCLC histology and Ki67>18% were established as negative prognostic factors after surgery for LC. Such factors were not found after surgery for BM. Conclusion: There are differences between primary LC and corresponding BM - in histology, immunohistochemical expression and proliferative activity, but there are no significant differences in vascularization. SCLC histology and Ki67>8% may represent negative prognostic factors after surgery for LC with BM.
引用
收藏
页码:1626 / 1637
页数:12
相关论文
共 50 条
[41]   Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases [J].
Tran, Thang N. ;
Selinger, Christina I. ;
Kohonen-Corish, Maija R. J. ;
McCaughan, Brian ;
Kennedy, Catherine ;
O'Toole, Sandra A. ;
Cooper, Wendy A. .
CLINICAL LUNG CANCER, 2016, 17 (01) :30-+
[42]   The Effects of smoking status and smoking history on patients with brain metastases from lung cancer [J].
Shenker, Rachel F. ;
McTyre, Emory R. ;
Ruiz, Jimmy ;
Weaver, Kathryn E. ;
Cramer, Christina ;
Alphonse-Sullivan, Natalie K. ;
Farris, Michael ;
Petty, William J. ;
Bonomi, Marcelo R. ;
Watabe, Kounosuke ;
Laxton, Adrian W. ;
Tatter, Stephen B. ;
Warren, Graham W. ;
Chan, Michael D. .
CANCER MEDICINE, 2017, 6 (05) :944-952
[43]   Irradiation of brain metastases from lung cancer: A retrospective study [J].
Bergqvist, M ;
Brattstrom, D ;
Bennmarker, H ;
Wagenius, G ;
Riska, H ;
Brodin, O .
LUNG CANCER, 1998, 20 (01) :57-63
[44]   Novel Systemic Treatments for Brain Metastases From Lung Cancer [J].
Bicky Thapa ;
Adam Lauko ;
Kunal Desai ;
Vyshak Alva Venur ;
Manmeet S. Ahluwalia .
Current Treatment Options in Neurology, 2018, 20
[45]   Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients [J].
Cacho-Diaz, B. ;
Spinola-Marono, H. ;
Mendoza-Olivas, L. G. ;
Monroy-Sosa, A. ;
Reyes-Soto, G. ;
Arrieta, O. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11) :1538-1542
[46]   Novel Systemic Treatments for Brain Metastases From Lung Cancer [J].
Thapa, Bicky ;
Lauko, Adam ;
Desai, Kunal ;
Venur, Vyshak Alva ;
Ahluwalia, Manmeet S. .
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (11)
[47]   Recurrent brain metastases from lung cancer: the impact of reoperation [J].
Munzir Al-Zabin ;
Winfried O. Ullrich ;
Alexander Brawanski ;
Martin A. Proescholdt .
Acta Neurochirurgica, 2010, 152 :1887-1892
[48]   Pronostic factors of synchronous brain metastases from lung cancer [J].
Penel, N ;
Brichet, A ;
Prevost, B ;
Duhamel, A ;
Assaker, R ;
Dubois, FO ;
Lafitte, JJ .
LUNG CANCER, 2001, 33 (2-3) :143-154
[49]   Intracranial Efficacy of Systemic Therapy in Patients with Asymptomatic Brain Metastases from Lung Cancer [J].
Sun, Min-Gwan ;
Park, Sue Jee ;
Kim, Yeong Jin ;
Moon, Kyung-Sub ;
Kim, In-Young ;
Jung, Shin ;
Oh, Hyung-Joo ;
Oh, In-Jae ;
Jung, Tae-Young .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
[50]   Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients [J].
B. Cacho-Díaz ;
H. Spínola-Maroño ;
L. G. Mendoza-Olivas ;
A. Monroy-Sosa ;
G. Reyes-Soto ;
O. Arrieta .
Clinical and Translational Oncology, 2019, 21 :1538-1542